Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cynata Therapeutics Limited ( (AU:CYP) ) has shared an announcement.
Cynata Therapeutics Limited announced a change in the director’s interest, specifically regarding Dr. Darryl Maher’s holdings. On November 29, 2025, 300,000 unlisted options exercisable at $0.97 expired, leaving Dr. Maher with 116,666 ordinary shares and 220,000 unlisted options exercisable at $0.185. This change reflects the expiration of certain options, which may impact the director’s future financial interests in the company.
More about Cynata Therapeutics Limited
Cynata Therapeutics Limited operates in the biotechnology industry, focusing on the development of stem cell therapies. The company is known for its proprietary Cymerus™ technology, which is designed to produce mesenchymal stem cells for therapeutic use, targeting various medical conditions.
YTD Price Performance: 18.75%
Average Trading Volume: 207,705
Technical Sentiment Signal: Buy
Current Market Cap: A$67.67M
See more data about CYP stock on TipRanks’ Stock Analysis page.